New CaviWipes 2.0 Fully Qualifies for EPA’s Emerging Viral Pathogen Claim1 for Optimal Infection Prevention

CaviWipes 2.0 meets urgent infection prevention needs with strong efficacy claims, excellent material compatibility, and an easy-to-use new label design.

Brea, CA (8/27/2020) — A leader in infection prevention, Metrex announces the early October 2020 launch of its new CaviWipes 2.0 surface disinfectant featuring a host of robust, in-demand features. In a recent comparative study1 conducted by Metrex, CaviWipes 2.0 is one of only five surface disinfectant wipes amongst leading competitor products to fully qualify for EPA’s rigorous Emerging Viral Pathogen claim2. As such, CaviWipes 2.0 is optimized to handle daily infection prevention needs as well as future public health crises. With its quick two-minute universal contact time, CaviWipes 2.0 delivers the excellent material compatibility CaviWipes customers know and trust, as well as strong efficacy claims infection preventionists demand.
Because emerging viral pathogens occur less frequently or predictably than established pathogens, not all EPA-registered disinfectants specify use against this category of infectious agents. CaviWipes 2.0 enters the market as one of the few exceptions.

“In times of crisis, professionals responsible for infection prevention in hospitals need access to quick-working surface disinfectants proven to be effective against emerging pathogens as well as established pathogens, viruses, and bacteria that can increase the risk of healthcare associated infections,” explains Yatao Liu, Vice President and General Manager at Metrex. “CaviWipes 2.0 delivers on these demands, as a surface disinfectant that has fully qualified for the EPA emerging pathogens program1. That means CaviWipes 2.0 is effective not only against today’s pathogens, but also potentially for future pathogens that await us.”

With a two-minute universal contact time, CaviWipes 2.0 also features a newly designed label that allows the user to quickly and easily find key information about efficacy and compatibility. “Like its predecessor, CaviWipes 2.0 is compatible with hard, non-porous surfaces commonly found in clinical settings,” says Liu. “With a redesigned label, end users will be able to see at a glance which pathogens, viruses, and bacteria CaviWipes 2.0 works against, as well as which surfaces it can be safely used on. This helps makes the critical job of infection prevention much easier.”

The CaviWipes brand has been used and trusted by clinicians for over 20 years. The next-generation CaviWipes 2.0 builds on this reputation with strong efficacy claims that are paramount during times of public health crises. “With robust efficacy claims, hospitals can use CaviWipes 2.0 with confidence and ease,” adds Liu. “That’s especially important when dealing with an unpredictable public health crisis.”

Following a soft launch in the United States as early as October 2020, CaviWipes 2.0 will be widely available on the market starting in 2021. To learn more, please visit or contact Denise Montenegro, Marketing Manager at (714) 817-5430 or email

  1. CaviWipes 2.0 qualifies for the EPA’s Emerging Viral Pathogen claim for all virus types (enveloped, large and small non-enveloped viruses). Refer to CaviWipes 2.0 Master Label at,P8_RINUM:531054,46781-17
  2. Data on file from Internal Study



Related Articles